Psychiatric NP Scope of Practice for Weight Loss/GLP-1 in Michigan

If you’re a psychiatrist or psychiatric prescriber who’s noticed the explosion in GLP-1 weight loss therapies and wondered ‘Can I offer this to my patients?’ — you’re not alone. The short answer: yes, psychiatrists can legally prescribe weight loss medications, including GLP-1s and controlled appetite suppressants, via telehealth in most states. But there’s a maze of federal DEA rules, state-specific prescribing laws, and scope-of-practice questions you need to navigate first.

Here’s what you actually need to know to stay compliant — and whether adding weight management makes sense for your practice.

The Federal Picture: DEA Telehealth Rules Are Extended (For Now)

Let’s start with the elephant in the room: controlled substances. Many weight loss medications — particularly older appetite suppressants like phentermine (Schedule IV) — fall under DEA jurisdiction. Pre-pandemic, the Ryan Haight Act required an in-person medical evaluation before you could prescribe any controlled substance via telemedicine.

COVID-19 changed that temporarily. And as of December 2026, those flexibilities are still active — the DEA and HHS extended the telemedicine waiver through the end of 2026 to prevent a ‘telehealth cliff’ while they finalize permanent regulations. What this means: right now, you can legally prescribe Schedule III-V controlled substances (like phentermine) via telehealth to new patients nationwide without an in-person visit, as long as you meet standard-of-care requirements.

But here’s the catch: this is temporary policy, not permanent law. The DEA has proposed new rules that will likely require either a ‘special telemedicine registration’ or impose limits (like initial 30-day supplies for certain Schedule II drugs). They’re also considering state-specific restrictions — for example, requiring the prescriber and patient to be in the same state for Schedule II stimulants.

What you should do now: Operate within current flexibilities but build your practice expecting these rules to tighten. Document everything meticulously, use state PDMPs religiously, and don’t build a business model that depends on indefinite federal waivers.

The GLP-1 loophole: Here’s the good news — GLP-1 agonists like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are NOT controlled substances. They’re completely unrestricted by DEA rules. You can prescribe them via telehealth across state lines (where you’re licensed) without any federal prescribing barriers. The only limitations are state-level standard-of-care requirements and your own clinical judgment.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrist Scope of Practice: Can You Prescribe for Weight Loss?

Short answer: Yes, legally. You hold an unrestricted medical license (MD/DO). There’s no separate ‘obesity medicine license.’ If you’re competent to manage a condition, you can treat it — whether that’s depression, ADHD, or obesity.

Practical reality: This gets complicated when you move outside your specialty training. State medical boards don’t forbid psychiatrists from treating obesity, but they will hold you to the standard of care that any reasonable physician treating obesity would follow. That means:

• Documenting appropriate patient selection (BMI ≥30 or ≥27 with comorbidities)
• Ordering relevant labs (thyroid function, metabolic panel, A1C if indicated)
• Providing or documenting counseling on diet, exercise, and behavioral modification
• Monitoring for side effects and titrating appropriately
• Following up regularly (many states mandate quarterly visits for weight loss patients)

Where this gets tricky for psychiatrists: You’re already managing psychiatric medications that affect metabolism. Adding GLP-1s or phentermine requires considering drug-drug interactions, metabolic effects, and cardiovascular risks. Phentermine is a stimulant — how does that interact with your patient’s anxiety disorder or lithium? GLP-1s cause GI side effects and affect blood sugar — are you prepared to manage those, or will you coordinate with their PCP?

The scope question for PMHNPs: If you’re a Psychiatric Nurse Practitioner, this is where things get stickier. Your scope of practice is defined by your training and certification in mental health. Prescribing purely for obesity — not as a side effect of psychiatric treatment — may fall outside your board-certified scope.

In states like Texas and Florida, you’d likely need explicit delegation from a supervising physician (ideally one with expertise in weight management, not just psychiatry). In states with NP independent practice (California after 2026, New York for experienced NPs), you technically could treat obesity independently, but professional liability insurers and state nursing boards might scrutinize whether you’re practicing outside your competency. Best practice: Get additional training in obesity medicine, work under collaborative agreements with physicians who have metabolic expertise, or position yourself as managing psychiatric comorbidities (binge eating disorder, depression affecting weight) rather than primary obesity treatment.

State-by-State Reality Check: Where the Rules Actually Bite

Federal rules set the floor. State laws often add ceilings. Here’s what actually matters in key states:

New York: The Strictest State for Controlled Substances

New York reinstated its in-person exam requirement for controlled substances as of May 2025. If you want to prescribe phentermine (Schedule IV) via telehealth in New York, you need to either:

• See the patient in person yourself at least once in 12 months
• Have another NY-licensed provider perform an in-person exam and share records
• Meet narrow exceptions (covering for a colleague, 5-day emergency supply for existing patient)

Practical impact: Many telehealth weight loss companies operating in NY now require at least one physical clinic visit or partner with local providers for initial exams. If you’re doing pure virtual psychiatry in NY and want to add weight management, you’ll need a hybrid model.

The good news: GLP-1s (semaglutide, tirzepatide) are NOT controlled substances, so New York’s in-person rule doesn’t apply. You can prescribe Wegovy via video visit with a thorough evaluation. You’ll also need to use New York’s mandatory e-prescribing system and check the I-STOP PDMP within 24 hours before prescribing any Schedule II-IV controlled substance (required for every prescription, not just the first).

Florida: Permissive for Telehealth, Strict on Obesity Standards

Florida explicitly allows telehealth for psychiatric treatment including Schedule II controlled substances — so you can prescribe Adderall via video for ADHD (Florida carved out an exception for psychiatric disorders). For weight loss, Schedule IV drugs like phentermine are permitted via telehealth.

But Florida imposes detailed obesity prescribing standards (Florida Admin Code 64B8-9.012):

• Document BMI ≥30 (or ≥27 with comorbidities)
• Obtain written informed consent outlining medication risks
• Re-evaluate patient at least every 3 months (in-person or video)
• Provide the patient with Florida’s ‘Weight-Loss Consumer Bill of Rights’

These rules apply to all physicians prescribing weight loss drugs — psychiatrists included. Florida also prohibits off-label prescribing of SSRIs for weight loss and bans advertising that guarantees specific results.

For NPs: Florida APRNs need physician supervision unless they’ve achieved autonomous practice status (which as of 2025 still excludes psychiatric NPs). A PMHNP in Florida would need a collaborating physician — and that physician should arguably have metabolic/obesity expertise, not just psychiatry credentials.

California: Progressive Telehealth, But Complex Practice Structure

California doesn’t require in-person visits for telehealth prescribing (including controlled substances), but it has strict documentation requirements:

• Obtain and document telehealth consent at first encounter (required by law)
• Check the CURES PDMP before first fill of any Schedule II-IV drug and every 4 months thereafter for ongoing controlled therapy
• Use mandatory e-prescribing

The big California curveball is the Corporate Practice of Medicine doctrine — only physician-owned professional corporations can provide medical services. If you’re launching a weight loss telehealth venture, it must be structured with a physician-owned entity, even if NPs or PAs are doing most of the clinical work. Non-physician investors can’t control clinical decisions.

California’s AB 890 (phased in through 2026) allows experienced Nurse Practitioners to practice independently in their certified population focus after 3 years of experience. But a PMHNP’s population focus is mental health — treating obesity as primary care is a gray area. You’d want additional training or certification to reduce risk.

Key California reality: Medi-Cal (California Medicaid) is eliminating coverage for GLP-1 weight loss medications in January 2026. This shifts the market heavily toward cash-pay or commercial insurance patients.

Texas: Standard Telehealth, But Delegation Is Key

Texas has no in-person exam requirement for telehealth (that was removed in 2017). You can prescribe weight loss medications via video visit if it meets the standard of care. Texas requires:

• Live audiovisual interaction (or store-and-forward with audio) to establish a valid relationship
• Checking the Texas PMP before prescribing opioids, benzos, barbiturates, or carisoprodol (phentermine isn’t on the mandatory list, but best practice is to check anyway)
• Sending a report to the patient’s PCP within 72 hours if they consent (coordination of care requirement)

For NPs and PAs: Texas requires a Prescriptive Authority Agreement with a supervising physician. That agreement must specifically authorize prescribing weight loss medications if the NP/PA will do so. NPs/PAs in Texas cannot prescribe Schedule II drugs outside hospital/hospice settings, but phentermine (Schedule IV) and GLP-1s are fair game under proper delegation.

Pennsylvania: Flexible But Undefined

Pennsylvania has no comprehensive telehealth statute. It defers to professional standards and federal rules. Pennsylvania providers can prescribe controlled substances via telehealth under the current DEA extension, but must:

• Check the PA PDMP before first prescription of opioids or benzos (required by law), and ideally check for all controlled substances including stimulants
• Meet the same standard of care as in-person (thorough history, appropriate evaluation)

Pennsylvania CRNPs (Certified Registered Nurse Practitioners) require collaborative agreements with physicians to prescribe. There’s no independent NP practice in PA yet (despite multiple legislative attempts). A PMHNP prescribing for weight loss would need a collaborating physician — again, ideally someone with obesity medicine credentials.

Illinois: Telehealth-Friendly with NP Independence

Illinois explicitly allows telehealth relationships and prescribing without in-person visits. Illinois also offers Full Practice Authority for APRNs after 4,000 hours of experience and additional coursework — meaning an experienced NP can prescribe independently, including controlled substances (with a consultation agreement for Schedule II opioids).

Illinois requires:

• Checking the Illinois PMP before first prescription of Schedule II narcotics and every 90 days for ongoing opioid therapy (other controlled substances recommended but not legally mandated)
• Using e-prescribing for all controlled substances (mandatory as of 2023)

Illinois doesn’t have obesity-specific prescribing rules — it follows standard medical practice. The state is generally supportive of telehealth expansion, making it a favorable environment for virtual weight management services.

The Real Economics: Why Platforms Like Klarity Make Sense

Let’s talk about what actually acquiring weight loss patients costs if you try to do it yourself:

DIY marketing reality check:

• Google Ads for ‘weight loss doctor’ or ‘GLP-1 near me’ cost $15-40+ per click. Most clicks don’t convert. A realistic cost per booked patient through PPC is $200-400+ after you factor in click-through rates, no-shows, and qualification.
• SEO takes 6-12 months of consistent investment (content creation, technical optimization, backlinks) before generating meaningful organic traffic. Most solo providers don’t have this expertise or patience.
• Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you’re competing with hundreds of other providers on the same search page. Zocdoc charges $35-100+ per booking plus subscription costs.
• Agency/consultant fees: If you hire help, expect $3,000-5,000/month in marketing spend with uncertain ROI for months.

When you add up agency costs, ad spend testing, staff time handling unqualified leads, and no-show rates from cold traffic, your true patient acquisition cost is typically $200-500+ per new patient — and that’s after months of building and optimizing campaigns.

The Klarity model: Instead of gambling thousands on marketing channels that might not work, you pay a standard listing fee per new patient lead who books with you. That’s it. No upfront marketing spend. No monthly subscriptions. No wasted ad budget on clicks that don’t convert. You only pay when a qualified patient — already matched to your specialty, availability, and insurance acceptance — actually books an appointment.

The value props that make this compelling:

• Pre-qualified patient flow: Patients are already seeking weight loss treatment and matched to your credentials
• Built-in infrastructure: Telehealth platform, scheduling, payment processing included (no separate EHR or video platform costs)
• Both insurance and cash-pay: Flexibility to see the patients you want
• You control your schedule: Only pay when you’re actually seeing patients
• Guaranteed ROI: You know exactly what each patient costs, versus throwing money at uncertain marketing channels

For most psychiatrists — especially those starting telehealth or expanding into weight management — this eliminates the biggest barrier: patient acquisition risk. You’re paying for performance, not promises.

How to Do This Compliantly (The Checklist)

If you’re adding weight management to your practice, here’s your compliance framework:

1. Get licensed in every state where patients are locatedTelehealth doesn’t bypass state licensure. Use the Interstate Medical Licensure Compact (IMLC) if your state participates to streamline multi-state licensing.

2. Document telehealth consentStates like California, Illinois, and others require explicit consent for telehealth services. Document it in your intake process (most platforms handle this automatically).

3. Conduct a thorough evaluationYour documentation must show:

• Comprehensive history (prior weight loss attempts, current medications, psych history)
• Physical exam elements you can assess via video (weight, BMI calculation, observation of patient’s general condition)
• Relevant labs ordered or reviewed (thyroid, metabolic panel, A1C)
• Informed consent discussion about medication risks, side effects, and expectations
• Diet, exercise, and behavioral counseling provided or coordinated

4. Use state PDMPs religiouslyBefore prescribing any controlled substance:

• New York: Check I-STOP PDMP within 24 hours before every Schedule II-IV prescription
• California: Check CURES before first fill and every 4 months for ongoing therapy
• Texas: Check before prescribing opioids/benzos/barbiturates (and best practice for phentermine)
• Pennsylvania: Check before first opioid/benzo and each refill
• Florida: Check E-FORCSE before prescribing any controlled substance to patients ≥16 years old
• Illinois: Check before Schedule II narcotics and every 90 days for ongoing opioid therapy

5. Follow state-specific obesity treatment rules

• Florida: Written informed consent, BMI documentation, quarterly follow-ups, Consumer Bill of Rights
• New Jersey (if expanding there): Requires psychiatric evaluation, diet/exercise counseling, ruling out endocrine causes before prescribing
• Virginia: Requires physical exam, lab work, follow-up within 30 days

6. Use e-prescribing for controlled substancesRequired in New York, California, Illinois, Texas, and most other states as of 2023.

7. Coordinate careShare information with the patient’s primary care physician (with patient consent). This is legally required in Texas within 72 hours; it’s best practice everywhere. You’re not treating obesity in a vacuum — patients often have diabetes, hypertension, or other metabolic conditions that need integrated management.

8. Set up proper follow-up protocolsMost states and clinical guidelines recommend:

• Initial: Monthly visits for first 3 months (titration period)
• Ongoing: At least every 3 months (Florida requires this by law)
• Labs: Periodic monitoring depending on medication (metabolic panels, renal function for GLP-1s)

9. Ensure proper business structureIf you’re in California or other states with corporate practice of medicine restrictions, your practice entity must be physician-owned. If you’re working with NPs or PAs, ensure proper delegation/collaboration agreements are in place and documented.

When This Makes Sense (And When It Doesn’t)

This is a good fit if:

• You’re already treating patients with medication-induced weight gain (antipsychotics, mood stabilizers) and want to offer comprehensive metabolic care
• You have patients with binge eating disorder or depression affecting weight where psychiatric and metabolic treatment overlap
• You’re comfortable managing side effects, drug interactions, and coordinating with PCPs
• You’re willing to invest in additional training (American Board of Obesity Medicine certification, CME in metabolic disorders)
• You want to expand your telehealth practice into a high-demand specialty with strong cash-pay revenue potential

This probably isn’t worth it if:

• You’re barely managing your current psychiatric caseload (adding weight management means more follow-ups, lab monitoring, coordination)
• You’re not interested in the medical complexities outside pure mental health
• Your state requires extensive physician supervision (as a PMHNP) and you can’t secure appropriate collaboration
• You’re in New York and not willing to see patients in person for initial controlled substance prescriptions

The hybrid model: Many psychiatrists find the sweet spot is treating psychiatric patients who also need weight management (addressing both conditions simultaneously), rather than marketing yourself as a pure ‘weight loss clinic.’ This keeps you within your core competency, reduces scope-of-practice risk, and provides genuinely integrated care.

FAQs

Can psychiatrists legally prescribe GLP-1 medications like Ozempic or Wegovy for weight loss?
Yes. Psychiatrists hold unrestricted medical licenses and can prescribe FDA-approved weight loss medications, including GLP-1 agonists. GLP-1s are not controlled substances, so there are no DEA restrictions. You must follow standard-of-care obesity treatment guidelines (appropriate patient selection, informed consent, regular monitoring).

Do I need an in-person visit to prescribe phentermine via telehealth?
It depends on your state. Under current federal rules (through December 2026), no in-person visit is required. However, New York requires at least one in-person exam within 12 months for any controlled substance prescription. Most other states (Texas, Florida, California, Illinois, Pennsylvania) allow telehealth-only prescribing of phentermine if you conduct an appropriate video evaluation. Always check your specific state’s medical board rules.

Can PMHNPs prescribe weight loss medications?
Legally, it varies by state and depends on your scope of practice. PMHNPs are certified in mental health, and treating obesity may be outside that scope unless you have additional training or it’s clearly related to psychiatric comorbidities (binge eating disorder, depression-related weight gain). In states requiring physician collaboration (Texas, Florida, Pennsylvania), you’d need a collaborative agreement with a physician who has expertise in obesity medicine. In states with NP independent practice (California post-2026, Illinois with FPA), you technically could practice independently but should ensure you’re practicing within your competency to avoid liability. Best practice: get additional training in obesity medicine or work collaboratively with physicians.

What are the DEA rules for prescribing controlled weight loss medications via telehealth in 2026?
The DEA temporarily extended COVID-era flexibilities through December 31, 2026, allowing providers to prescribe Schedule III-V controlled substances (like phentermine) via telehealth without an in-person exam. However, this is temporary policy while permanent rules are developed. Providers still need valid DEA registration, must comply with state laws (which may be stricter), and should use state PDMPs before prescribing. Expect new requirements (like special telemedicine registration or supply limits) when permanent rules are finalized.

Which states have the strictest telehealth prescribing laws for weight loss medications?
New York is currently the strictest — requiring an in-person medical evaluation before prescribing any controlled substance (with narrow exceptions). Florida prohibits teleprescribing Schedule II controlled substances (except for psychiatric disorders), but allows Schedule IV drugs like phentermine via telehealth. Florida also has detailed obesity treatment rules (BMI documentation, quarterly follow-ups, written consent). California requires checking the PDMP frequently and has complex business structure rules. Virginia and New Jersey (if expanding there) impose comprehensive evaluation requirements before starting weight loss medications.

Do I need to check state prescription monitoring databases before prescribing weight loss drugs?
For controlled substances (phentermine), yes — most states legally require PDMP checks:

• New York: Every prescription
• California: First fill and every 4 months
• Texas: Before opioids/benzos (phentermine recommended)
• Pennsylvania: First fill of opioids/benzos (best practice for all controlled)
• Florida: Before every controlled substance prescription
• Illinois: Schedule II narcotics (best practice for all)

For non-controlled GLP-1s (semaglutide, tirzepatide), PDMP checks aren’t legally required, but it’s good practice to check for any controlled substances the patient might be taking that could interact or indicate substance use concerns.

What training or certification do I need to prescribe weight loss medications as a psychiatrist?
Legally, none — your medical license allows you to prescribe FDA-approved medications for any indication within your competence. However, obtaining certification from the American Board of Obesity Medicine (ABOM) significantly strengthens your credibility, reduces liability risk, and ensures you’re practicing to current standards. Additional CME in metabolic disorders, nutrition, and obesity pharmacotherapy is recommended. If you’re expanding into weight management, document your training and expertise.

The Bottom Line

Can psychiatrists prescribe weight loss medications via telehealth? Absolutely — and there’s legitimate clinical overlap (medication-induced weight gain, binge eating disorder, depression affecting metabolic health) where psychiatric and obesity treatment intersect.

But this isn’t a ‘quick side hustle.’ It requires understanding federal DEA rules (currently flexible through 2026 but likely to tighten), navigating state-specific prescribing laws (especially for controlled substances like phentermine), ensuring you’re practicing within standard of care for obesity treatment, and coordinating care appropriately.

The economic reality: acquiring weight loss patients through DIY marketing costs $200-500+ per patient after months of investment and uncertain results. Platforms like Klarity eliminate that risk entirely — you pay only when qualified patients actually book with you, with built-in infrastructure and no upfront marketing spend.

If you’re interested in expanding your telehealth practice into weight management, do it thoughtfully: get proper training, ensure your business structure is compliant, document meticulously, use PDMPs religiously, and coordinate with patients’ other providers. Done right, this can be clinically rewarding and financially sustainable. Done wrong, it’s a fast track to board complaints and liability.

Ready to explore adding weight management to your practice without the marketing risk? Join Klarity’s provider network to get matched with qualified patients seeking GLP-1 and obesity treatment — no upfront costs, just pay when patients book.

Sources and References

1. U.S. Department of Health & Human Services – Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026)
   https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (Florida Telehealth Act, 2019, accessed November 2025)
   http://www.leg.state.fl.us/statutes/

3. Florida Administrative Code 64B8-9.012 – Standards for the Prescription of Drugs to Treat Obesity (Effective August 8, 2022)
   https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

4. Goodwin Law – Client Alert: ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (March 30, 2024)
   https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. California Medical Association – News: ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal’ (December 2, 2025)
   https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

This content is for informational purposes only and does not constitute legal or medical advice. Providers should consult with healthcare attorneys and their state medical boards for specific guidance on telehealth prescribing and obesity treatment regulations.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated